Premium
DT‐01‐04: The efficacy of RVT‐101, a 5‐ht6 receptor antagonist, as an adjunct to donepezil in adults with mild‐to‐moderate Alzheimer's disease: Completer analysis of a phase 2b study
Author(s) -
Lombardo Ilise,
Ramaswamy Geetha,
Piscitelli Stephen C.,
Friedhoff Lawrence
Publication year - 2015
Publication title -
alzheimer's and dementia
Language(s) - Uncategorized
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2015.08.154
Subject(s) - donepezil , placebo , medicine , antagonist , randomized controlled trial , dementia , clinical endpoint , disease , receptor , pathology , alternative medicine
Paulo Fontoura, Luca Santarelli, F. Hoffmann-La Roche Ltd, Basel, Switzerland; F. Hoffmann-La Roche, Ltd., Basel, Switzerland; VU University Medical Center, Amsterdam, Netherlands; Fundacio ACE, Barcelona, Spain; Hôpital La Salpêtri ere, Paris, France; Formerly of F. Hoffmann-La Roche Ltd, Basel, Switzerland; Roche Products Limited, Welwyn Garden City, United Kingdom; Roche Products Ltd, Welwyn Garden City, United Kingdom. Contact e-mail: Robert.lasser.rl1@roche. com